세계의 섬유아세포 성장인자 시장 보고서(2025년)
Fibroblast Growth Factors (FGFs) Global Market Report 2025
상품코드 : 1764318
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,568,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,494,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,420,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

섬유아세포 성장인자 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 덧붙여 바이오테크놀러지의 지속적인 진보, 제약회사와 연구기관의 협력관계의 확대가 견인할 것으로 예측됩니다.

만성질환의 유병률 증가는 향후 몇 년간의 섬유아세포 성장인자 시장의 성장을 가속할 것으로 예측됩니다. 당뇨병 등의 질환의 리스크를 높이기 때문입니다. 예를 들어, 2024년 6월 영국 국민건강서비스는 2023년 일반의에게 등록된 비당뇨병성 고혈당증(당뇨병 전단계) 진단을 받은 사람이 361만 5,330명으로 2022년 306만 5,825명보다 18% 증가했다고 보고했습니다.

섬유아세포 성장인자 시장의 주요 기업은 치료 효과를 향상시키고, 부작용을 최소화하고, 만성 및 변성 질환의 재생 치료를 지원하기 위해 인공 FGF 변이체와 같은 기술적으로 고급 제품의 개발을 선호합니다. 변종은 안정성, 표적 특이성 및 효능을 높이고 조직 복구 및 질병 관리에서 치료 성과를 최적화하도록 설계된 섬유아세포 성장인자의 변형입니다. 예를 들어, 2022년 10월, 미국에 본사를 둔 생명공학 회사인 지티야 제네시스 메디신은 파킨슨병 치료를 목표로 하는 혁신적인 FGF-1 치료제를 출시했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

KTH
영문 목차

영문목차

Fibroblast growth factors (FGFs) are a group of signaling proteins essential for regulating cell growth, tissue repair, and development. They primarily promote fibroblast proliferation and differentiation, playing a key role in processes such as wound healing, embryonic development, angiogenesis, and metabolic regulation.

The major product types of fibroblast growth factors include recombinant fibroblast growth factor, purified fibroblast growth factor, endogenous fibroblast growth factor, and others. Recombinant fibroblast growth factor is synthetically produced through genetic engineering techniques to generate large quantities for therapeutic and research purposes. These are categorized by type into palifermin, erdafitinib, infigratinib, futibatinib, and others. FGFs are used in a wide range of applications, including oncology, hematology, wound healing, dermatology, cardiovascular disease, bone and musculoskeletal disorders, and tissue regeneration. The primary end users include pharmaceutical companies, biotechnology firms, research institutes, and others.

The fibroblast growth factors (FGFs) market research report is one of a series of new reports from The Business Research Company that provides fibroblast growth factors (FGFs) market statistics, including the fibroblast growth factors (FGFs) industry global market size, regional shares, competitors with the fibroblast growth factors (FGFs) market share, detailed fibroblast growth factors (FGFs) market segments, market trends, and opportunities, and any further data you may need to thrive in the fibroblast growth factors (FGFs) industry. This fibroblast growth factors (FGFs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fibroblast growth factors (FGFs) market size has grown rapidly in recent years. It will grow from $0.86 billion in 2024 to $1.34 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. Growth during the historic period can be attributed to the rising demand for regenerative medicine, increased utilization of FGFs in wound healing applications, growing funding for cancer research, advancements in biopharmaceutical innovation, and heightened awareness of the therapeutic potential of fibroblast growth factors (FGFs).

The fibroblast growth factors (FGFs) market size is expected to see rapid growth in the next few years. It will grow to $1.34 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. Growth in the forecast period is expected to be driven by rising investments in personalized medicine, increased adoption of fibroblast growth factor (FGF)-based therapies, the growing prevalence of chronic diseases, ongoing advancements in biotechnology, and expanding collaborations between pharmaceutical companies and research institutions. Key trends anticipated during this period include progress in targeted drug delivery systems, development of advanced biomaterials for FGF delivery, innovation in gene editing technologies, advancements in sustained-release formulations, and the emergence of novel combination therapies.

The increasing prevalence of chronic diseases is expected to drive the growth of the fibroblast growth factors (FGFs) market in the coming years. Chronic diseases are long-lasting health conditions that develop gradually and often require ongoing medical attention. This rise in chronic illnesses is partly linked to sedentary lifestyles, as reduced physical activity and prolonged sitting heighten the risk of conditions such as heart disease and diabetes. FGFs contribute to managing chronic diseases by facilitating tissue repair and regeneration, making them valuable in the treatment of long-term conditions. They aid healing, slow disease progression, and improve patient outcomes and quality of life. For example, in June 2024, the UK's National Health Service reported that 3,615,330 individuals registered with general practitioners were diagnosed with non-diabetic hyperglycemia (pre-diabetes) in 2023-an 18% increase from 3,065,825 cases in 2022. This surge underscores the growing need for effective therapies like FGFs. Thus, the rising burden of chronic diseases is fueling demand in the FGFs market.

Major companies in the fibroblast growth factors (FGFs) market are prioritizing the development of technologically advanced products, such as engineered FGF variants, to improve therapeutic efficacy, minimize side effects, and support regenerative treatments for chronic and degenerative conditions. Engineered FGF variants are modified forms of fibroblast growth factors designed to enhance stability, target specificity, and potency, thereby optimizing therapeutic outcomes in tissue repair and disease management. For example, in October 2022, Zhittya Genesis Medicine, a US-based biotechnology firm, introduced an innovative FGF-1 therapy aimed at treating Parkinson's disease. This therapy utilizes intranasal delivery to stimulate angiogenesis and neuronal regeneration within the brain. The FGF-1 treatment represents a promising advancement in slowing disease progression and enhancing quality of life for affected individuals.

In January 2022, Thermo Fisher Scientific Inc., a US-based biotechnology company, acquired PeproTech Inc. for approximately $1.85 billion. This acquisition was intended to strengthen Thermo Fisher's capabilities in cell and gene therapy by broadening its portfolio of recombinant proteins, including fibroblast growth factors (FGFs), which are essential components in cell culture media and regenerative medicine applications. PeproTech Inc., also based in the US, is a biotechnology company that specializes in recombinant FGFs for research and regenerative medicine purposes.

Major players in the fibroblast growth factors (fgfs) market are Merck & Co. Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Wako Pure Chemical Corporation, Lonza Group AG, Miltenyi Biotec B.V. & Co. KG, GenScript Biotech Corporation, 89bio Inc., R&D Systems Inc., ACROBiosystems Co. Ltd., Elabscience Biotechnology Inc., Cell Signaling Technology Inc., BPS Bioscience Inc., Proteintech Group Inc., Akero Therapeutics Inc., MedChemExpress LLC, Defined Bioscience Inc., Gold Biotechnology Inc. (GoldBio), Nucleus Biologics LLC, ZellBio GmbH, Affinity Biosciences Ltd., GeneCards.

North America was the largest region in the fibroblast growth factors (FGFs) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fibroblast growth factors (FGFs) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fibroblast growth factors (FGFs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fibroblast growth factors (FGFs) market consists of sales of fibroblast growth factors (FGFs)-based therapeutic proteins, growth factor supplements for cell culture, and related biologics used in wound healing, tissue regeneration, and cosmetic applications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fibroblast Growth Factors (FGFs) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fibroblast growth factors (fgfs) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for fibroblast growth factors (fgfs) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fibroblast growth factors (fgfs) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Fibroblast Growth Factors (FGFs) Market Characteristics

3. Fibroblast Growth Factors (FGFs) Market Trends And Strategies

4. Fibroblast Growth Factors (FGFs) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Fibroblast Growth Factors (FGFs) Growth Analysis And Strategic Analysis Framework

6. Fibroblast Growth Factors (FGFs) Market Segmentation

7. Fibroblast Growth Factors (FGFs) Market Regional And Country Analysis

8. Asia-Pacific Fibroblast Growth Factors (FGFs) Market

9. China Fibroblast Growth Factors (FGFs) Market

10. India Fibroblast Growth Factors (FGFs) Market

11. Japan Fibroblast Growth Factors (FGFs) Market

12. Australia Fibroblast Growth Factors (FGFs) Market

13. Indonesia Fibroblast Growth Factors (FGFs) Market

14. South Korea Fibroblast Growth Factors (FGFs) Market

15. Western Europe Fibroblast Growth Factors (FGFs) Market

16. UK Fibroblast Growth Factors (FGFs) Market

17. Germany Fibroblast Growth Factors (FGFs) Market

18. France Fibroblast Growth Factors (FGFs) Market

19. Italy Fibroblast Growth Factors (FGFs) Market

20. Spain Fibroblast Growth Factors (FGFs) Market

21. Eastern Europe Fibroblast Growth Factors (FGFs) Market

22. Russia Fibroblast Growth Factors (FGFs) Market

23. North America Fibroblast Growth Factors (FGFs) Market

24. USA Fibroblast Growth Factors (FGFs) Market

25. Canada Fibroblast Growth Factors (FGFs) Market

26. South America Fibroblast Growth Factors (FGFs) Market

27. Brazil Fibroblast Growth Factors (FGFs) Market

28. Middle East Fibroblast Growth Factors (FGFs) Market

29. Africa Fibroblast Growth Factors (FGFs) Market

30. Fibroblast Growth Factors (FGFs) Market Competitive Landscape And Company Profiles

31. Fibroblast Growth Factors (FGFs) Market Other Major And Innovative Companies

32. Global Fibroblast Growth Factors (FGFs) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fibroblast Growth Factors (FGFs) Market

34. Recent Developments In The Fibroblast Growth Factors (FGFs) Market

35. Fibroblast Growth Factors (FGFs) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기